Skip to main content
OpenTrials
Completed

NCT Number: NCT01526252

Reference Population for Speckle Tracking Imaging

The SCAR study uses a software program entitled QLAB, a proprietory program, developed by Philips Healthcare (Philips Healthcare, Andover, MA). Literature on two-dimensional speckle tracking imaging (2DSTE) is growing, but data relevant to the population in the SCAR study is minimal. Accumulation of data relevant for a population of subjects will provide a set of normal values for interpretation of 2DSTE and minimize any influences from differences in data produced from different companies. This data may also assist other researchers investigate other cardiac diseases and abnormalities.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Left Ventricular Function

Age range

20 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Ottawa Heart Institute

Ottawa, Ontario, K1Y 4W7, Canada

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Be between the ages of 20 - 80 years at study entry
  • Provide written informed consent and be able to comply with study procedures, including permission to access medical records
  • Have a BMI index equal to or less than 35
  • Less than 5% risk of developing coronary artery disease as determined using the Combined Diamond/Forrester and CASS data (ACC Stable CAD Guidelines)

Exclusion criteria

  • Have taken cardioactive drugs within 6 months prior to examination
  • These include but are not limited to beta-blockers, calcium channel blockers, and angiotensin converting enzyme inhibitors
  • Currently clinically significant chronic or acute illness
  • Documented cardiovascular disease
  • Possess abnormal cardiac structure and function after examination with routine ECHO
  • This may include valvular defects, left ventricular hypertrophy, cardiomyopathies or pericardial disease
  • Documented congenital heart conditions or defects
  • History of diabetes
  • Be unwilling to provide voluntary consent

Treatment and study plan

Primary outcomes

  1. Establishment of normal values data in males and females aged 20 - 80

    Time frame: 1 year

Sponsors and collaborators

Lead sponsor

Ottawa Heart Institute Research Corporation

Other

Registry information

Official study title

Establishing a Reference Population for Normal Left Ventricular Function Parameters to Validate the Use of Two Dimensional Speckle Tracking Imaging Software in the Scar Study

Acronym: STE Normal

Important dates

Study start
2011
Primary completion
2012
Study completion
2015
First posted
Feb 3, 2012
Registry last updated
Apr 24, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.